360 NEWS360 NEWS

Business · National

Biocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathway

The approval marks a regulatory milestone for Biocon and expands its portfolio of oncology biosimilars approved in Europe and the United States.

Verified Timeline

No verified timeline updates.

Voluntary Reader Opinion

What is your view on “Biocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathway”?

This is self-selected reader participation, not representative scientific polling.